NASDAQ:MDGL - Madrigal Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $84.61 +1.16 (+1.39 %) (As of 02/28/2020 12:27 PM ET) Add Compare Today's Range$81.61Now: $84.61▼$85.4850-Day Range$76.98MA: $86.51▼$93.4952-Week Range$74.05Now: $84.61▼$148.18Volume4,419 shsAverage Volume118,123 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/ABeta1.01 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MDGL Previous Symbol CUSIP87162T20 CIK1157601 Webhttp://www.madrigalpharma.com/ Phone267-824-2827Debt Debt-to-Equity RatioN/A Current Ratio29.44 Quick Ratio29.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$30.99 per share Price / Book2.73Profitability EPS (Most Recent Fiscal Year)($5.45) Net Income$-32,810,000.00 Net MarginsN/A Return on Equity-18.44% Return on Assets-17.92%Miscellaneous Employees17 Outstanding Shares15,430,000Market Cap$1.31 billion Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive MDGL News and Ratings via Email Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MDGL Rates by TradingView Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions What is Madrigal Pharmaceuticals' stock symbol? Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL." How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) issued its quarterly earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.67) by $0.13. The company's quarterly revenue was down 100.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.75) earnings per share. View Madrigal Pharmaceuticals' Earnings History. When is Madrigal Pharmaceuticals' next earnings date? Madrigal Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Madrigal Pharmaceuticals. What price target have analysts set for MDGL? 8 brokers have issued 1 year target prices for Madrigal Pharmaceuticals' stock. Their forecasts range from $126.00 to $215.00. On average, they expect Madrigal Pharmaceuticals' stock price to reach $161.00 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price. View Analyst Price Targets for Madrigal Pharmaceuticals. What is the consensus analysts' recommendation for Madrigal Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Madrigal Pharmaceuticals. What are Wall Street analysts saying about Madrigal Pharmaceuticals stock? Here are some recent quotes from research analysts about Madrigal Pharmaceuticals stock: 1. According to Zacks Investment Research, "Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. " (2/27/2020) 2. HC Wainwright analysts commented, "We are confident that the MAESTRO-NASH trial is well-managed: it is conducted by PRA Health Sciences (private), a top CRO that was awarded the 2019 CRO a top drawer group of clinical site investigators including principal investigator Dr. Antonio, TX. Importantly, MAESTRO-NASH’s 52-week treatment period was selected in order to optimize patient compliance and the repeat biopsy rate, as both drop off considerably in trials that last more than one year." (7/3/2019) 3. Stifel Nicolaus analysts commented, "We believe resmetirom’s Phase 2b data are encouraging on NASH resolution and emerging evidence continues to point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. We are positively biased heading into Phase 3 however; we see few company specific catalysts to drive shares upward in the next ~12-18 months and think the stock could be volatile around updates from competitors (i.e. VKTX, GNFT, etc.) – this leads to our Hold rating. Ultimately, we feel MDGL will largely remain range bound before it reports Phase 3, 52-week data in 2H21 and based on our diligence for our NASH white paper (link here), we suspect any strategic acquirer would want to confirm resmetirom’s safety/efficacy profile and gain some commercial validation for the NASH category, as a whole, before paying a large price tag for MDGL. So a near-term takeout is unlikely, in our view." (6/24/2019) Has Madrigal Pharmaceuticals been receiving favorable news coverage? News headlines about MDGL stock have trended extremely negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Madrigal Pharmaceuticals earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Madrigal Pharmaceuticals. Are investors shorting Madrigal Pharmaceuticals? Madrigal Pharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 2,570,000 shares, an increase of 6.6% from the January 30th total of 2,410,000 shares. Based on an average daily trading volume, of 190,200 shares, the short-interest ratio is currently 13.5 days. Currently, 26.0% of the company's stock are sold short. View Madrigal Pharmaceuticals' Current Options Chain. Who are some of Madrigal Pharmaceuticals' key competitors? Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Viking Therapeutics (VKTX), Advaxis (ADXS), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Consolidated Water (CWCO), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Crispr Therapeutics (CRSP). Who are Madrigal Pharmaceuticals' key executives? Madrigal Pharmaceuticals' management team includes the folowing people: Dr. Paul A. Friedman, Chairman & CEO (Age 76)Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)Mr. Thomas W. Hare, Sr. VP of Clinical Management Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (11.00%), State Street Corp (2.97%), Alliancebernstein L.P. (2.28%), Jennison Associates LLC (1.79%), Goldman Sachs Group Inc. (1.07%) and Laurion Capital Management LP (0.88%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Fred B Craves, Marc R Schneebaum, Paul A Friedman and Rebecca Taub. View Institutional Ownership Trends for Madrigal Pharmaceuticals. Which major investors are selling Madrigal Pharmaceuticals stock? MDGL stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, SG Americas Securities LLC, Citigroup Inc., Rafferty Asset Management LLC, Bank of Montreal Can, Bank of America Corp DE and New York State Common Retirement Fund. View Insider Buying and Selling for Madrigal Pharmaceuticals. Which major investors are buying Madrigal Pharmaceuticals stock? MDGL stock was acquired by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Goldman Sachs Group Inc., Alliancebernstein L.P., Aviva PLC, Capital Research Global Investors, Credit Suisse AG, Geode Capital Management LLC and Prudential Financial Inc.. Company insiders that have bought Madrigal Pharmaceuticals stock in the last two years include Fred B Craves and Paul A Friedman. View Insider Buying and Selling for Madrigal Pharmaceuticals. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Madrigal Pharmaceuticals' stock price today? One share of MDGL stock can currently be purchased for approximately $84.61. How big of a company is Madrigal Pharmaceuticals? Madrigal Pharmaceuticals has a market capitalization of $1.31 billion. The biopharmaceutical company earns $-32,810,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe.View Additional Information About Madrigal Pharmaceuticals. What is Madrigal Pharmaceuticals' official website? The official website for Madrigal Pharmaceuticals is http://www.madrigalpharma.com/. How can I contact Madrigal Pharmaceuticals? Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 267-824-2827 or via email at [email protected] MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 379 (Vote Outperform)Underperform Votes: 282 (Vote Underperform)Total Votes: 661MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What is the Beige Book?
